AB-FUBINACA
|
AB-FUBINACA
N-[1-Amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide |
|
| N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide | |
| Synthetic cannabinoids | |
| Synthetic cannabinoid receptor agonists |
|
| 1185282-01-2 | |
|
|
InChI=1S/C20H21FN4O2/c1-12(2)17(19(22)26)23-20(27)18-15-5-3-4-6-16(15)25(24-18)11-13-7-9-14(21)10-8-13/h3-10,12,17H,11H2,1-2H3,(H2,22,26)(H,23,27)
|
|
AKOOIMKXADOPDA-UHFFFAOYSA-N
|
|
|
O=C(C1=NN(CC2=CC=C(F)C=C2)C3=C1C=CC=C3)NC(C(C)C)C(N)=O
|
|
| C20H21FN4O2 | |
| 368.4048 g/mol | |
| 71/II | |
| 2020 | |
|
This substance is included in Schedule II of the 1971 Convention on Psychotropic Substances. |